ACP-196 (acalabrutinib)

DRUG2 trials

Sponsors

Acerta Pharma BV

Conditions

Chronic Lymphocytic LeukemiaMantle Cell Lymphoma (MCL)

Phase 2

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Active, not recruitingNCT02213926

Acerta Pharma BVMantle Cell Lymphoma (MCL)

Start: 2015-03-02End: 2026-09-06Updated: 2026-08-04

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Active, not recruitingNCT02717611

Acerta Pharma BVChronic Lymphocytic Leukemia

Start: 2016-03-08End: 2026-06-06Updated: 2026-03-25

Related Papers

Abstract 5559: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) in BTKi-treated mantle cell lymphoma

Cancer Research2025-04-21

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma

eJHaem2024-06-241 citations

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

Hematological Oncology2021-06-015 citations

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Blood2020-11-0410 citations

Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Journal of Clinical Oncology2019-05-209 citations

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

2017-12-11299 citations

Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study

Blood2016-12-0222 citations

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Blood2016-09-07187 citations